{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:32:05Z","timestamp":1792085525016,"version":"4.4.0"},"reference-count":61,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The Fourth Batch of Hospital Key Discipline Construction Program of Fujian Medical University Union Hospital","award":["2021FLK01KY"],"award-info":[{"award-number":["2021FLK01KY"]}]},{"name":"Beijing Continent Pharmaceuticals Co., Ltd.","award":["no grant number"],"award-info":[{"award-number":["no grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,10,7]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Radiation-induced lung injury (RILI) is one of the most clinically-challenging toxicities and dose-limiting factors during and\/or after thoracic radiation therapy for oesophageal squamous cell carcinoma (ESCC). With limited effective protective drugs against RILI, the main strategy to reduce the injury is strict adherence to dose-volume restrictions of normal lungs. RILI can manifest as acute radiation pneumonitis with cellular injury, cytokine release and cytokine recruitment to inflammatory infiltrate, and subsequent chronic radiation pulmonary fibrosis. Pirfenidone inhibits the production of inflammatory cytokines, scavenges-free radicals and reduces hydroxyproline and collagen formation. Hence, pirfenidone might be a promising drug for RILI prevention. This study aims to evaluate the efficacy and safety of pirfenidone in preventing RILI in patients with locally advanced ESCC receiving chemoradiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is designed as a randomised, placebo-controlled, double-blinded, single-centre phase 2 trial and will explore whether the addition of pirfenidone during concurrent chemoradiation therapy (CCRT) could prevent RILI in patients with locally advanced ESCC unsuitable for surgery. Eligible participants will be randomised at 1:1 to pirfenidone and placebo groups. The primary endpoint is the incidence of grade &gt;2 RILI. Secondary endpoints include the incidence of any grade other than grade &gt;2 RILI, time to RILI occurrence, changes in pulmonary function after CCRT, completion rate of CCRT, disease-free survival and overall survival. The follow-up period will be 1 year. In case the results meet the primary endpoint of this trial, a phase 3 multicentre trial with a larger sample size will be required to substantiate the evidence of the benefit of pirfenidone in RILI prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the Ethics Committee of Fujian Union Hospital (No. 2021YF001-02). The findings of the trial will be disseminated through peer-reviewed journals, and national and international conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2100043032.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-060619","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T10:56:25Z","timestamp":1666868185000},"page":"e060619","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03902509","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03902509","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Cheng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies), Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"Department of Medical Imaging Technology, School of Medical Imaging, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors, Fujian Medical University, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-296X","authenticated-orcid":false,"given":"Bangwei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Nosocomial Infection Control Branch, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xue","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqin","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of PET\/CT Center, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies), Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"Department of Medical Imaging Technology, School of Medical Imaging, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors, Fujian Medical University, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology Department, The Second Hospital of Zhangzhou, Zhangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqiang","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-1254","authenticated-orcid":false,"given":"Benhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological, and Breast Malignancies), Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"Department of Medical Imaging Technology, School of Medical Imaging, Union Clinical Medical College, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors, Fujian Medical University, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2025121514124546000_12.10.e060619.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"2025121514124546000_12.10.e060619.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206113262403"},{"key":"2025121514124546000_12.10.e060619.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1623"},{"key":"2025121514124546000_12.10.e060619.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1167"},{"key":"2025121514124546000_12.10.e060619.5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1442-2050.2009.01003.x","article-title":"Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma","volume":"23","author":"Li","year":"2010","journal-title":"Dis Esophagus"},{"key":"2025121514124546000_12.10.e060619.6","first-page":"832","article-title":"Analysis of related factors of radiation pneumonitis after radiotherapy for thoracic segment esophageal cancer","volume":"40","author":"Du","year":"2020","journal-title":"Zhong Hua Fang She Yi Xue Yu Fang Hu Za Zhi"},{"key":"2025121514124546000_12.10.e060619.7","unstructured":"Cao Y , Shen W , Zhu S . Low dose volume of lung in predicting acute radiation pneumonitis in patients with middle and lower thoracic esophageal cancer. Zhong Liu Fang Zhi Yan Jiu 2015:32\u20136."},{"key":"2025121514124546000_12.10.e060619.8","first-page":"66","article-title":"Clinical and dosimetric factors associated with acute radiation-induced pneumonitis in esophageal carcinoma patients after intensity modulated radiation therapy (IMRT)","volume":"0","author":"Zhen","year":"2019","journal-title":"Zhen Duan Xue Li Lun Yu Shi Jian"},{"key":"2025121514124546000_12.10.e060619.9","unstructured":"Wu W , Tan Y , Xiao N , et al . Analysis of influencing factors of radiation-induced lung injury in patients with esophageal cancer treated by IMRT. Tian Jin Yi Yao 2019:159\u201362."},{"key":"2025121514124546000_12.10.e060619.10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3748\/wjg.v10.i8.1098","article-title":"Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma","volume":"10","author":"Fu","year":"2004","journal-title":"World J Gastroenterol"},{"key":"2025121514124546000_12.10.e060619.11","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2019.08.024","article-title":"A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiation therapy","volume":"105","author":"Wang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121514124546000_12.10.e060619.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.10.017"},{"key":"2025121514124546000_12.10.e060619.13","first-page":"842","article-title":"Prognostic analysis of intensity-modulated radiotherapy for cervical and upper thoracic esophageal carcinoma","volume":"29","author":"Shen","year":"2020","journal-title":"Zhong Hua Fang She Zhong Liu Xue Za Zhi"},{"key":"2025121514124546000_12.10.e060619.14","first-page":"397","article-title":"Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients","volume":"7","author":"Orditura","year":"2000","journal-title":"Oncol Rep"},{"key":"2025121514124546000_12.10.e060619.15","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31805c139a"},{"key":"2025121514124546000_12.10.e060619.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01757-0"},{"key":"2025121514124546000_12.10.e060619.17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(24)38125-X","article-title":"Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"289","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"2025121514124546000_12.10.e060619.18","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007023532508"},{"key":"2025121514124546000_12.10.e060619.19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"2025121514124546000_12.10.e060619.20","first-page":"L311","article-title":"Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level","volume":"276","author":"Gurujeyalakshmi","year":"1999","journal-title":"Am J Physiol"},{"key":"2025121514124546000_12.10.e060619.21","first-page":"779","article-title":"Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters","volume":"125","author":"Iyer","year":"1995","journal-title":"J Lab Clin Med"},{"key":"2025121514124546000_12.10.e060619.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(96)03845-3"},{"key":"2025121514124546000_12.10.e060619.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0736-z","article-title":"Pirfenidone improves survival in IPF: results from a real-life study","volume":"18","author":"Margaritopoulos","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2025121514124546000_12.10.e060619.24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1164\/rccm.201602-0258RR","article-title":"Pirfenidone for idiopathic pulmonary fibrosis","volume":"194","author":"Adams","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121514124546000_12.10.e060619.25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CM9.0000000000001032","article-title":"Progress in the mechanism of radiation-induced lung injury","volume":"134","author":"Ying","year":"2020","journal-title":"Chin Med J"},{"key":"2025121514124546000_12.10.e060619.26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2020.11.020","article-title":"Idiopathic pulmonary fibrosis: current knowledge, future perspectives and its importance in radiation oncology","volume":"155","author":"T\u00fcrkkan","year":"2021","journal-title":"Radiother Oncol"},{"key":"2025121514124546000_12.10.e060619.27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1667\/RR15017.1","article-title":"Antifibrotic agent pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat Res"},{"key":"2025121514124546000_12.10.e060619.28","unstructured":"National Comprehensive Cancer Network . Esophageal and esophagogastric junction cancers (version 3), 2021."},{"key":"2025121514124546000_12.10.e060619.29","unstructured":"USDOHAH S . Common terminology criteria for adverse events (CTCAE), 2017. Available: https:\/\/ctepcancergov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_85x11pdf"},{"key":"2025121514124546000_12.10.e060619.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2004.02.015"},{"key":"2025121514124546000_12.10.e060619.31","doi-asserted-by":"publisher","DOI":"10.1148\/rg.313105096"},{"key":"2025121514124546000_12.10.e060619.32","doi-asserted-by":"publisher","DOI":"10.1148\/rg.244035160"},{"key":"2025121514124546000_12.10.e060619.33","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v6.i9.708"},{"key":"2025121514124546000_12.10.e060619.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2009.10.029"},{"key":"2025121514124546000_12.10.e060619.35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.diii.2016.06.019","article-title":"Imaging after radiation therapy of thoracic tumors","volume":"97","author":"Ghaye","year":"2016","journal-title":"Diagn Interv Imaging"},{"key":"2025121514124546000_12.10.e060619.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.02.006"},{"key":"2025121514124546000_12.10.e060619.37","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyh107"},{"key":"2025121514124546000_12.10.e060619.38","first-page":"772","article-title":"Preliminary report of pirfenidone for the prevention of radiation pneumonitis in patients with esophageal cancer: analysis using inverse probability of treatment weighting","volume":"48","author":"Chen","year":"2021","journal-title":"Chin J Clin Oncol"},{"key":"2025121514124546000_12.10.e060619.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.149"},{"key":"2025121514124546000_12.10.e060619.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)01444-5"},{"key":"2025121514124546000_12.10.e060619.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.1743"},{"key":"2025121514124546000_12.10.e060619.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.11.013"},{"key":"2025121514124546000_12.10.e060619.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01758-2"},{"key":"2025121514124546000_12.10.e060619.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01669-2015"},{"key":"2025121514124546000_12.10.e060619.45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00026-2015"},{"key":"2025121514124546000_12.10.e060619.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025121514124546000_12.10.e060619.47","first-page":"560","article-title":"Pirfenidone in prevention and treatment of radiation pulmonary fibrosis","volume":"6","author":"Ji","year":"2010","journal-title":"Zhong Hua Fang She Zhong Liu Xue Za Zhi"},{"key":"2025121514124546000_12.10.e060619.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.01.027"},{"key":"2025121514124546000_12.10.e060619.49","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-2-19"},{"key":"2025121514124546000_12.10.e060619.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1314530"},{"key":"2025121514124546000_12.10.e060619.51","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321600"},{"key":"2025121514124546000_12.10.e060619.52","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.21037\/jtd.2017.08.146","article-title":"The NeoRes trial: Questioning the benefit of radiation therapy as part of neoadjuvant therapy for esophageal adenocarcinoma","volume":"9","author":"Stiles","year":"2017","journal-title":"J Thorac Dis"},{"key":"2025121514124546000_12.10.e060619.53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.21147\/j.issn.1000-9604.2019.02.01","article-title":"Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"2025121514124546000_12.10.e060619.54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.055"},{"key":"2025121514124546000_12.10.e060619.55","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","article-title":"Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial","volume":"3","author":"Suntharalingam","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025121514124546000_12.10.e060619.56","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01411","article-title":"External validation of radiation-induced dyspnea models on esophageal cancer radiotherapy patients","volume":"9","author":"Shi","year":"2019","journal-title":"Front Oncol"},{"key":"2025121514124546000_12.10.e060619.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38414-5"},{"key":"2025121514124546000_12.10.e060619.58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcma.2016.01.013","article-title":"Feasibility of intensity-modulated radiotherapy for esophageal cancer in definite chemoradiotherapy","volume":"79","author":"Hsieh","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"2025121514124546000_12.10.e060619.59","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199409000-00012"},{"key":"2025121514124546000_12.10.e060619.60","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.2147\/CMAR.S160909","article-title":"Dose-Escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2025121514124546000_12.10.e060619.61","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-014-0465-1"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-060619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:12:56Z","timestamp":1765836776000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-060619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,27]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjopen-2021-060619"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-060619","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}